Seizures are the most common presenting symptom in patients with gliomas. [7] [8] [9] [10] When uncontrolled, tumor-related epilepsy has a significant impact on patients' QOL, causes cognitive deterioration, and may result in significant morbidity. [11] [12] [13] [14] The persistence of seizures and the use of anti-epileptic drugs (AEDs) may negatively influence QOL and cognitive function. 11, 13 More than one third of patients with anaplastic gliomas experience epileptic seizures at disease onset, [15] [16] [17] [18] [19] and not all anaplastic gliomas are associated with seizures, despite having similar histology and tumor location. It is likely that variability in the presence of seizures cannot be explained entirely by tumor-related factors, but instead may be a complex interaction between tumor-related and genetic factors. Although, to date, some susceptibility candidate genes associated with tumor-related seizures have been identified in low-grade gliomas, 20, 21 few studies have focused on anaplastic gliomas.
To investigate molecular genetic profiles that might correlate with the presence of seizures, and the possible correlation between tumor-related seizures and survival outcome in Chinese patients with anaplastic gliomas, we retrospectively analyzed a series of 198 gliomas, including 39 anaplastic oligodendrogliomas, 103 anaplastic oligoastrocytomas, and 56 anaplastic astrocytomas, for clinicopathological factors and survival, with respect to tumorrelated seizures.
Methods

Patients
We retrospectively identified all patients (>18 years old) with anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), anaplastic oligoastrocytoma (AOA) from the Chinese Glioma Genome Atlas (CGGA), who underwent surgical resection at the Glioma Treatment Center of Beijing Tiantan Hospital from January 2006 to July 2012. Histological diagnosis was reaffirmed by two independent neuropathologists and graded according to the WHO classification. 1 Cases with discrepancies were re-reviewed by another pathologist until a consensus was reached. Clinical data, including patient's age at diagnosis, sex, presenting symptoms, preoperative Karnofsky performance status (KPS) score, and operation status, were obtained from medical records. OS time, defined as the period from surgery to death, was collected when patients visited the clinics and in phone interviews with patients and/or their relatives. Progression-free survival (PFS) was defined as the time of surgery until radiographic progression (the appearance of a new lesion or an increase in tumor size of !25%). Patients who were lost to follow-up or who died of nonprimary diseases were excluded. This study was approved by the Ethics Committee of Beijing Tiantan Hospital, and written informed consent was obtained from all patients.
Preoperative seizure characteristics
Data on seizure characteristics included date of seizure onset and type of seizure (simple partial, complex partial, and generalized seizures). The study population was divided into two groups based on preoperative seizure status.
Tumor location
Tumor location was considered to be the lobe or region of the brain within which the bulk of the glioma resided. These assignments were based on an evaluation of medical records and imaging study results, mainly MRI characteristics including tumor side (left, right, or bilateral) and specific lobe involvement (frontal, temporal, parietal, occipital, and insula).
Samples
Tumor tissue samples were obtained by surgical resection before treatment with radiation and/or chemotherapy. Resected specimens were snap-frozen and stored in liquid nitrogen until DNA extraction or paraffin-embedding.
DNA extraction
Genomic DNA was isolated from frozen tumor tissues using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. DNA concentration and quality were measured using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Houston, TX, USA).
Molecular evaluations
All data from the CGGA for which biomaterial was available, IDH mutation status (pyro-sequencing for IDH1/2 mutation), MGMT promoter methylation (DNA pyro-sequencing), and Ki-67 expression level (immunohistochemistry) were assessed according to routine methods. The 1p/19q fluorescent probe kit (Vysis Inc., Downers Grove, IL, USA) was used for FISH. Briefly, 4-mm-thick paraffin slides were deparaffinized, dehydrated, and incubated in 1 mol/L NaSCN for 35 min at 80 8C. Slides were then immersed in pepsin solution (0.65% in protease buffer with 0.01 mol/L HCl) for 10 min at 37 8C, and tissues were fixed with 10% neutral buffered formalin. Then, the specimens were dehydrated in an ethanol series (70%, 85%, and 100%, 2 min in each bath) and air-dried, 20 ml of each probe was added separately, and slides were sealed with rubber cement. After co-denaturation for 10 min at 75 8C, the slides were then placed in a humidified atmosphere with Hybrite (ThermoBrite, Vysis) for 16 h at 37 8C. Slides were immersed first in 2Â SSC/0.3% NP-40 for 2 min at RT (room temperature) and then in 2Â SSC/0.3% NP-40 for 2 min at 73 8C. After drying, nuclei were counterstained with 4,6-diamidino-2-phenylindole (DAPI) and anti-fade compound (p-phenylenediamine). FISH signals for each locus-specific FISH probe were assessed under an Olympus BX51TRF microscope (Olympus, Ina-shi, Nagano, Japan) equipped with a triple-pass filter (DAPI/Green/Orange; Vysis). The assessment and interpretation of FISH results were made according to guidelines defined by the SIOP Europe Neuroblastoma Pathology and Biology and Bone Marrow Group. 24 For each probe, more than 100 non-overlapping nuclei were enumerated per hybridization. Tumors with more than 30% of nuclei showing DNA loss were defined as tumors with chromosomal loss.
Analysis of EGFR amplification by fluorescence in situ hybridization (FISH)
A probe for the EGFR locus (7p11.2), labeled with Texas Red, was used in combination with a fluorescein isothiocyanatelabeled centromeric probe for chromosome 7. The procedure was performed according to the manufacturer's instructions (Cytocell, Cambridge, UK). The tissue section was incubated at 56 8C overnight, deparaffinized in xylene, hydrated in 100% and 70% ethanol, and treated with 0.1 M HCl at RT for 20 min. After incubation in the pretreatment reagent (Abbott Molecular Inc., Des Plaines, IL, USA) at 80 8C for 30 min, the section was digested with pepsin (2 mg/mL in 0.01 M HCl) at 37 8C for 10À20 min and dehydrated in an ethanol series. The probe set was applied, and the section was covered with a coverslip and sealed with rubber cement. For denaturation, the slides were incubated at 75 8C for 5 min; for hybridization, they were placed in a humidified chamber at 37 8C overnight. Post-hybridization washes were performed in 0.4Â saline sodium citrate buffer (0.4Â SSC)/Nonidet P-40 (NP-40; pH 7.0) at 72 8C for 2 min and in 2Â SSC/NP-40 (pH 7.0) at RT for 1 min. After washing and drying at RT, the slide was counterstained with 4 0 -6-diamidino-2-phenylindole I (10 ng/mL; Abbott Molecular Inc.) and analyzed via FISH. FISH results were represented as the ratio of EGFR to chromosome 7 centromeric signals from 50 non-overlapping tumor cell nuclei. Gene amplification was defined as the presence of EGFR gene clusters and !2.0 or !15 copies of EGFR per cell in !10% of the total cells.
Follow-up
Survival data were collected by clinics during patient visits and/ or in phone interviews. Patients who underwent biopsy only were not followed up at our center, and were therefore excluded from the survival analysis.
Statistical analysis
All statistical analyses were performed using SPSS version 13.0 (SPSS, Chicago, IL, USA) and were tailored to address associations between the presence of preoperative seizures and clinicopathological characteristics and survival outcomes. Survival function curves were calculated using the Kaplan-Meier method, and differences were evaluated using the log-rank test. Univariate analyses were carried out using the chi-square test for dichotomous variables and the Mann-Whitney U-test for continuous nonparametric data. All variables associated with preoperative seizures in univariate analysis (P < 0.05) were then included in a backward stepwise multivariate logistic regression model. A probability value of 0.05 was considered statistically significant after two-sided P-values were computed.
Results
Patient clinicopathological characteristics
We searched the database of the CGGA to find patients who had undergone primary resection of cerebral anaplastic gliomas between January 2006 and July 2012. This study group comprised 198 patients (114 males and 84 females; age range, 18-74 years; median age, 43 years) who were >18 years of age and who had WHO grade III disease. The breakdown of patients was as follows: 56 with AA, 39 with AO, and 103 with AOA diagnosed by histopathology. We excluded patients who had undergone secondary resection or needle biopsy only and those with infratentorial anaplastic gliomas. The main clinical characteristics of the 198 patients are summarized in Table 1 .
The pretreatment KPS scores ranged from 30 to 100 (median, 80). Tumor location was analyzed using MRI characteristics; 90 tumors were located in the left cerebral hemisphere, 85 in the right side, and 15 bilaterally. The most commonly involved lobe was the frontal (n = 114, 57.6%), followed by the temporal (n = 80, 40.4%), the parietal (n = 29, 14.6%), the insula (n = 23, 11.6%), and the occipital (n = 20, 10.1%).
All of the patients were successfully analyzed for LOH 1p, LOH 19q, 1p/19q codeletion, and EGFR amplification. We also collected available data on IDH1 mutation (n = 161), IDH2 mutation (n = 140), MGMT promoter methylation (n = 32), TP 53 mutation (n = 104), PTEN mutation (n = 100), and IHC-based Ki-67 protein expression levels (n = 177).
Seizure semiology
The seizure types of the 198 patients with anaplastic gliomas are listed in To identify factors that might be associated with preoperative seizures, demographic and tumor information was compared between patients with seizures and those without (see Table 1 for a complete list). In the univariate analysis, only five variables were significantly associated with the presence of seizures: frontal lobe involvement (frontal lobe involved vs. not involved, P = 0.01, chisquare test), occipital lobe involvement (occipital lobe involved vs. not involved, P = 0.08), tumor in the left cerebral hemisphere (left vs. right and bilateral, P = 0.036), EGFR amplification (amplified vs. not amplified, P = 0.025), and Ki-67 expression level (high expression vs. low expression, P = 0.027). Representative immunohistochemical staining for Ki-67 using a scale of 0-3 (0 = low, 3 = high expression) and FISH analysis of EGFR amplification with negative and positive results are shown in Figs. 2 and 3 , respectively. No other clinical or pathological variables were found to be associated with an increased risk for preoperative seizures in this group of patients. In the multivariate analysis, four of the five factors were found to have a strong association with preoperative seizures: frontal lobe involvement, left side involvement, low Ki-67 expression level and EGFR amplification were independent factors for a higher incidence of preoperative seizures (P-values, odds ratios, and 95% confidence intervals are shown in Table 2 ).
The prognostic value of preoperative seizures in anaplastic gliomas
Of the 198 anaplastic glioma patients, the median OS and PFS were 1314 days and 764 days, respectively. Patients with preoperative seizures had a longer OS compared to those without seizures (median: 1924 days vs. 923 days, P = 0.048, Table 3 and Fig. 1a) . For PFS, patients with preoperative seizures also showed better prognosis, but without statistical significance (median: 947 days vs. 548 days, P = 0.155, Table 3 and Fig. 1b ).
Discussion
Seizures play an important role in patients' postoperative QOL, 25 especially patients with low-grade gliomas (LGGs) and anaplastic gliomas, because of the duration of their survival. At present, there are two hypotheses by which the pathogenesis of tumor-related seizures can be explained. The first hypothesis involves the mechanical compression of the normal tissue surrounding the tumor because of mass effect, resulting in the affected tissue becoming an epileptic focus following ischemia and hypoxia. The basis of the other hypothesis is that the tumor itself excretes chemical factors that change the peritumoral microenvironment into an epileptic focus. Chang et al. 7 observed that the extent of tumor resection might be an independent factor predicting epileptic prognosis. A few researchers have explored the second hypothesis. Bordey and Sontheimer 26, 27 reported that astrocytic tumor cells might generate action potentials, which might themselves be the source and propagation route of epileptic activity. Other studies 28, 29 demonstrated that glioma cells released glutamate and killed peritumoral neurons by an excitotoxic mechanism. These findings revealed an important role of glutamate in the genesis of glioma-related seizures. Each of the two explanations is possible. Our previous studies 20,21,30 on LGGs also showed that LOH 19q, age, cortical involvement, and expression of miR-196b were associated with the occurrence of preoperative seizures. Based on the assumption that the biological behavior of gliomas may to some extent be related to the presence of seizures, we retrospectively analyzed a data-set from 198 Chinese patients who were diagnosed with cerebral hemispheric anaplastic gliomas. We aimed to identify the clinicopathological factors associated with preoperative seizures and the differences in survival outcome between patients with and without preoperative seizures. This large cohort of anaplastic glioma patients was treated at a single institute in China over a period of 6 years.
The percentage of patients presenting with seizures (34.3%) is consistent with that (35-45%) reported in previously published studies concerning anaplastic gliomas. [31] [32] [33] Some prior studies have also indicated that oligodendroglial tumors, including oligodendrogliomas and oligoastrocytomas, are more frequently associated with seizures than with astrocytomas. 33 However, our data did not show any significant difference in seizure incidence associated with the three different tumor types. This may be due to differences in the histological diagnostic criteria used in different hospitals. Different authors have suggested various histological cut-off values for the oligodendroglial component to separate oligoastrocytomas from astrocytomas. In our center, an oligoastrocytoma was pathologically diagnosed only if the proportion of oligodendroglial components reached 25% in at least 5-10 different planes. Otherwise, it was considered to be a ''pure'' astrocytoma. 21 In this study, we confirmed a previous finding by Chang et al. 7 that seizure occurrence is closely related to the location of tumors. Gliomas with frontal involvement tend to be associated with a higher incidence of preoperative seizures. Specifically, we demonstrated that patients with tumors located in the left cerebral hemisphere were more likely to present with seizures. This could be explained by the fact that our patients were mainly right-handed with a left-side dominant hemisphere, which means the functional location is mainly in the left hemisphere (e.g. Broca's area). An observational retrospective multicenter study conducted in 1509 patients with diffuse
LGGs demonstrated the result that tumor anatomical and functional locations were predictive of epileptic seizure incidence. 34 Lesions with left cerebral hemisphere involvement might be related with higher incidence of seizures because it is these functional cortical areas through which the epileptic activities manifest clinical symptoms during seizure. Of the 68 patients who presented with preoperative seizures, we identified two important molecular pathological characteristics; low Ki-67 expression and positive EGFR amplification. Based on the second hypothesis concerning the pathogenesis of tumorrelated seizures outlined previously, these molecular genetic effects may alter the balance between intracortical inhibitory and excitatory mechanisms, therefore inducing epileptogenic activity. Tumor-correlated biomarkers have been a popular research topic during the past 20 years. Several studies on the pathogenesis of both idiopathic and symptomatic epilepsy have identified a number of seizure-related candidate genes. [35] [36] [37] Previously, we have shown a relationship between Ki-67 expression and seizure prognosis. 20, 21 In this study, we further confirmed that Ki-67 might influence preoperative seizures in anaplastic gliomas. Prayson found that proliferating cells appeared to be primarily astrocytic and endothelial in nature, and suggested that malformation of cortical development lesions may not be static. 38 Kee et al.
provided evidence implicating Ki-67 as a marker of proliferation in the initial phase of adult neurogenesis. 39 Our results are consistent with these findings. Rush found that 86% of Ki-67-positive cells also expressed protein patched homolog 1 (a component of the Hedgehog pathway), and showed a significant correlation between the expression of the Hedgehog pathway and Ki-67 in 20 pilocytic astrocytomas. These results indicate that Ki-67 may, to some extent, play a role in seizure-related tumors by increasing proliferation. Furthermore, lower Ki-67 expression is usually associated with more benign tumors, which may also be related to increased incidence of preoperative seizures. In addition, we speculate that Ki-67 may become a novel diagnostic or therapeutic target for tumor-related seizures in the future. EGFR is a tyrosine kinase that binds to extracellular EGF and dimerizes, thus mediating signal transduction across the cell membrane. This signal elicits a downstream cascade through the mitogen-activated protein kinase/extracellular signal-regulated kinase and phosphatidylinositol 3-kinase/Akt pathways that are generally favorable to growth and cell migration. 40 Although such signaling is critical for normal organism development, glioma cells frequently use EGFR signaling to promote tumor behavior. Gliomas employ several methods to up-regulate EGFR signaling including overexpression of the receptor via disrupted regulatory feed-back, thereby sensitizing the cell to extracellular EGF; overexpression via EGFR gene amplification on 7p12; and a truncation mutation, producing a constitutively active EGFRvIII. 41 Furthermore, the likelihood of EGFR amplification increases with WHO glioma grade and is most common in GBM. 42 In this study, EGFR amplification was shown to be an independent predictor for preoperative seizures in patients with anaplastic gliomas, a finding that has not been previously reported. There may be two reasons to explain this result. First, anaplastic gliomas may mask an adverse impact of EGFR in their grade II oligodendrogliomas. 40 Our data of 198 patients with grade III tumors showed a slight association between longer survival and EGFR amplification, although this association did not reach the level of statistical significance. However, this finding has precedence in the literature, with two previous reports that EGFR expression is closely correlated with EGFR amplification and is related to longer survival in grade III anaplastic oligdendroglial tumors; this is the exact opposite of what was seen in their grade II counterparts. 40, 43 It should be noted that this may be difficult to explain from a biological perspective, considering the pro-oncogenic effects of EGFR but this might explain the correlation of EGFR amplification and increased incidence of preoperative seizures in grade III gliomas. The second explanation is that the effect of EGFR amplification in gliomas depends greatly on tumor grade, thus, raising the question of whether there are any differences in expression profiles between different grades that might account for this. For example, Akt activation can trigger matrix metalloproteinase expression via a p300-dependent mechanism, 44 yet p300 expression is lower in grade III versus grade II gliomas. 45 Alternatively, excessive oncogene signaling can LGGs (WHO grade II) with more benign biological behavior and comparatively better survival. The other hypothesis is based on tumor location. Lesions with greater cortical involvement tend to be associated with a higher incidence of preoperative seizures, as shown in our previous study. 21 Tumors with cortical involvement are always more likely to be totally resected, and patients with total tumor resection tend to have better survival. In contrast to previous studies, 7 however, we did not find that patients with IDH mutation status, 1p/19q deletion, tumors of the temporal lobe, and tumors with oligodendroglial component subtypes were significantly more likely to present with seizures. These negative findings could be due to several reasons such as differences in study design and the different populations studied. Future research should focus on identifying susceptibility candidate genes for tumor-related seizures in larger multicenter studies, including low-and high-grade gliomas with and without symptomatic seizures. This is the first study involving a large number of Chinese patients with anaplastic gliomas from a single center conducted to identify clinicopathological susceptibility factors for tumor-related seizures, and survival differences between patients with and without preoperative seizures. Our findings offer useful insights into the pathogenesis of preoperative seizures in anaplastic gliomas. Specifically, Ki-67 expression and EGFR amplification correlated with preoperative seizures, and are potential pathological biomarkers. Our results may provide useful information for the current management of patients with anaplastic gliomas suffering from symptomatic seizures. However, prospective studies are needed to provide better evidence to guide clinical decision making.
In summary, epilepsy is one of the major issues facing patients with anaplastic gliomas. It significantly impacts on patients' QOL. Frontal involvement, left cerebral hemisphere involvement, and EGFR amplification, as well as low-level Ki67 expression, predisposed patients to a favorable outcome in terms of preoperative seizures in the current study. Thus, these factors may provide insights into developing effective treatment strategies aimed at prolonging patient survival.
